Eli Lilly shares phase 3 data on triple agonist weight loss drug retatrutide

Investing.com Gold reports: Eli Lilly shares phase 3 data on triple agonist weight loss drug retatrutide. Full body text was unavailable at ingest time, so this brief is based on headline context.